Aravax Ltd, a developer of immunotherapies for food allergy, has appointed Louise Peacock as chief regulatory and quality officer, based at the company’s Oxford, UK site. The Australia-headquartered company’s lead product, PVX108, is in a Phase 2 trial for the treatment of peanut allergy. Ms Peacock previously was head of pharma R&D at Nestle Health Science/Aimmune Therapeutics and while at Aimmune, she was responsible for supporting the development and marketing approvals for an oral immunotherapy to treat peanut allergy approved by the US Food and Drug Administration.
Copyright 2025 Evernow Publishing Ltd